Keryx Biopharmaceuticals Inc. (KERX): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Keryx Biopharmaceuticals ( KERX) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.1%. By the end of trading, Keryx Biopharmaceuticals rose 43 cents (6.5%) to $7.05 on heavy volume. Throughout the day, 13.2 million shares of Keryx Biopharmaceuticals exchanged hands as compared to its average daily volume of 6.4 million shares. The stock ranged in a price between $6.56-$7.35 after having opened the day at $6.59 as compared to the previous trading day's close of $6.62. Other companies within the Health Care sector that increased today were: Atossa Genetics ( ATOS), up 25.2%, StemCells ( STEM), up 21%, ZIOPHARM Oncology ( ZIOP), up 17.5%, and Albany Molecular Research ( AMRI), up 15.7%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, together with its subsidiaries, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment cancer and renal disease. Keryx Biopharmaceuticals has a market cap of $476.1 million and is part of the drugs industry. Shares are up 152.7% year to date as of the close of trading on Monday. Currently there are six analysts that rate Keryx Biopharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Keryx Biopharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, weak operating cash flow, generally disappointing historical performance in the stock itself and poor profit margins.

On the negative front, Celsion Corporation ( CLSN), down 10.4%, Apricus Biosciences ( APRI), down 9.7%, Pernix Therapeutics Holdings ( PTX), down 9.5%, and Unilife Corporation ( UNIS), down 8.8%, were all laggards within the health care sector with Quest Diagnostics ( DGX) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.

null

More from Markets

U.S. Crude Oil Hits Fresh 3-Year Highs as Gasoline Heads to $3 a Gallon

U.S. Crude Oil Hits Fresh 3-Year Highs as Gasoline Heads to $3 a Gallon

Stocks Waver Amid Progress on U.S.-China Trade; Dow Slips

Stocks Waver Amid Progress on U.S.-China Trade; Dow Slips

Jim Cramer: Schlumberger Predicted the Rise in Oil Prices

Jim Cramer: Schlumberger Predicted the Rise in Oil Prices

Jim Cramer on Zillow's New Business: Buying and Selling Homes

Jim Cramer on Zillow's New Business: Buying and Selling Homes

Jim Cramer on the Markets: It's Natural to Have Some Profit Taking

Jim Cramer on the Markets: It's Natural to Have Some Profit Taking